UNSPSC 51262912: Mepindolol sulfate

This classification denotes a beta-adrenergic blocking agent 2C15H22N2O2.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 63523X4FBA, chemically known as 2-propanol, 1-((1-methylethyl)amino)-3-((2-methyl-1h-indol-4-yl)oxy)-, sulfate (2:1), but more generally known as mepindolol sulfate, which bears US NIH Compound Identifier 6917859. European Medicines Agency schedules Mepindolol sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03157MIG.

Most nations, for tariff and trade purposes, schedule mepindolol sulfate under HS 29339990 and SITC 51577. As of Q4 2014, MEPINDOLOL SULFATE remains US FDA's Preferred Term for this commodity. SMILES: CC1CC2C([NH]1)CCCC2OCC(CNC(C)C)O.CC1CC2C([NH]1)CCCC2OCC(CNC(C)C)O.OS(=O)(=O)O.

UNSPSC 51262912 Mepindolol sulfate is a Commodity code for a specific pharmaceutical ingredient, but the recent state and local opportunities posted under this code do not align with mepindolol procurement. Instead, the opportunities reflect broader pharmaceutical and pharmacy benefit management services — naloxone supply, drug deactivation systems, and direct-to-manufacturer prescription program implementation. The mismatch suggests that this code sees minimal or misaligned recent activity in state and local procurement, and business development professionals should verify the actual commodity or service scope needed before pursuing opportunities tagged to this code.

Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023 (note: the deadline date appears inconsistent with the posting date and may reflect a data error in the source). The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, requesting vendor information on direct-to-manufacturer prescription programs for self-insured health plans and state agencies, with no formal deadline or award structure at the information-gathering stage. Neither opportunity directly involves mepindolol sulfate or pharmaceutical ingredient procurement as the code nominally suggests. The geographic activity appears concentrated in Florida and Texas, but the misalignment between the code's nominal scope and the opportunities actually posted indicates that this code may not be a reliable indicator of active state and local pharmaceutical ingredient sourcing.